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Abstract
Introduction: Maintenance hemodialysis (HD) patients’ 
morbidity and mortality remain unacceptably high. It is 
important to identify risk factors affecting outcome and 
define their relative contribution. 
Methods: The data of 93 patients who started HD at 
the Sheffield Kidney Institute between January 1997 
and June 1998 were analyzed retrospectively. Potential 
risk predictors of 5-year survival were evaluated both at 
baseline and at 1-year follow-up, including changes from 
baseline. 
Results: Patients median age was 60 years (range: 27-80), 
75% were males and 23% were diabetics. According to 
the Index of Co-Existing Disease (ICED) score, 18% of 
patients were level 0-1 (low comorbidity), 56% level 
2 and 26% level 3. The 5-year survival was 58%. The 
Cox models identified eight independent time-adjusted 
risk factors for 5-year survival, the importance of which 
as independent predictors was confirmed by logistic 
regression models. According to the artificial neural 
network (ANN) models, the relative importance of these 
factors was as follows: age (26.6%), baseline systolic 
blood pressure  (24.1%),  mean Kt/V during the first year 
(19.7%), baseline ICED score (14.8%), baseline diastolic 
blood pressure  (8.6%),  serum calcium change from 
baseline (2.8%), blood urea change from baseline (2.1%), 
serum creatinine change from baseline (1.3%). This ANN 
model had a high level of predictive performance as 
assessed by accuracy (93.3%) and by Receiver Operating 
Characteristic (ROC) curve analysis (AUC=0.92). 
Conclusion: Integrated use of regression analysis and 
probabilistic models allow computation of individual 
risk of mortality in HD. This may help in optimizing care 
and costs. 
Key Words: hemodialysis, risk factors, ICED, artificial 
neural network
Introduction
The annual mortality rates in maintenance hemodialysis 
(HD) patients remain high, from 9% in Japan to 16% 
in Europe to 24% in the United States, on average. In 
the United States, only one third of dialyzed patients 
survive 5 years, and mortality of cardiovascular origin 
is 10-20 times greater than in the general population [1]. 
Comorbidity, advanced age and increased frequency of 
cardiovascular risk factors all contribute to outcome. It 
is now generally accepted that many factors leading to 
premature death in dialysis patients are already present 
when patients are started on renal replacement therapy 
(RRT). Among these, baseline congestive heart failure 
[2, 3], diabetes [4] and malnutrition [5] have strong 
impacts on prognosis. Even when these factors are taken 
into account, survival is still shorter in this particular 
group of individuals than in the normal population. 
Early identification of baseline risk factors that may 
be amenable to therapeutic intervention, has a greater 
practical attraction because their correction may reduce 
dialysis mortality.
A number of predictive analyses of outcome on HD have 
been undertaken over the years. Previous studies have, 
in general, assessed comorbidity at the start of dialysis 
treatment [6, 7] but there are very scarce data on the 
subsequent changes in comorbidity [8]. Whether changes 
in comorbidity are measurable by the current instruments 
and the extent to which changes in comorbidity alter 
the mortality-risk remain to be determined. The 
Artificial Neural Network (ANN) is a learning system 
based on a computational technique, which attempts 
to simulate the neurological processing ability of the 
brain [9]. Individual risk of progression to a given 
event can be effectively predicted by probabilistic tools 
such as artificial intelligence neural network models. 
These models offer an overall better performance 
than traditional statistical methods as they are not 
constrained by assumptions of specific relationships 
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between dependent and independent variables. They can 
powerfully model the complex non-linear relationships 
in different subgroups of the population. However, the 
final output is strongly dependent on the choice of the 
input variables (risk factors). Potential input parameters 
can be assessed by expert opinions [9] or, better, through 
multifactorial analyses [10]. In addition to identifying 
factors significantly associated with a given outcome, 
the ANN can order risk factors according to their relative 
importance and is particularly effective when data are 
incomplete, imprecise or noisy [10]. 
Our aim in this study was to identify risk markers/factors 
for low 5-year survival on HD, and to compare the 
performance of ANN and multivariate logistic regression 
models in the prediction of mortality in HD. 
Methods 
Patients and Study design
This is a single cohort, retrospective study that 
investigated the role of baseline and follow-up clinical 
and socio-demographic parameters in predicting the 
5-year survival of patients on HD. All patients who 
started HD at the Sheffield Kidney Institute (SKI) in the 
period between January 1997 and June 1998 and who 
have survived more than 90 days on HD were included 
in the analysis. Data were collected retrospectively from 
the hospital computer database and the patients' files, and 
included demographic (age, gender and race), baseline 
and follow-up clinical (causes of renal disease, comorbid 
conditions and causes of death) and biochemical 
(serum urea, creatinine, calcium, phosphorus, calcium-
phosphorus product, protein, albumin, hemoglobin, 
hematocrit and ferritin) data. Data were also collected 
on dialysis adequacy, including urea reduction ration 
(URR) and Kt/V, as well as on duration and causes of 
hospital admissions. Follow up data were collected at 
three months intervals for 5 years.
Potential predictors of 5-year survival were evaluated 
twice, at baseline and at 1-year follow-up. The relative 
change in biochemical parameters and comorbidity score 
during this period was also considered as a potential 
predictor of 5-year survival. The relative change was 
calculated according to the following equation:
Percent change = [(1-year value – baseline value)/ 
(baseline value)] X 100
Comorbidity assessment (ICED score)
Comorbidity is defined as a medical condition other than 
the primary disease. For the assessment of comorbidity in 
this study, we adapted the Index of Co-Existing Disease 
(ICED) score from the HEMO study [1] by excluding 
HIV. The ICED scoring system is based on medical 
record review of 17 medical conditions summarized in 
the Index of Disease Severity (IDS) which ranges from 
0-3, and 11 physical functions summarized in the Index 
of Physical Impairment (IPI) which ranges from 0-2. The 
final ICED score which ranges from 0-3 is determined 
after assessment of the IDS and IPI scores. 
Statistical analysis 
The main outcome, 5-year patients’ survival, and gender 
were considered as binary variables.  The ICED score was 
employed as a numerical ordinal variable. All remaining 
variables were considered as continuous variables. 
Data management and the algorithm of the integrated 
approach
Three groups of models were constructed to identify 
markers of survival in HD: (A) the first group of models 
assessed potential markers at baseline; (B) the second 
group of models assessed variables at 1-year follow up 
and included their relative change from baseline; and 
(C) the third group of models assessed a combination of 
the best independent predictors from group (A) and (B). 
Factors found at univariate analysis to be significantly 
associated with the outcome, which later retained 
an independent predictive value at the multivariate 
backward likelihood-ratio Cox regression analysis, were 
used to construct predictive optimal logistic regression 
(multivariate backwards likelihood-ratio) and/or ANN 
models. 
Artificial intelligence neural network modeling 
(ANN)
Data were approximately partitioned in random into 3 
sub-sets: 70% training set, 15% validation set and 15% 
test set. A class of ANN models was created and the best 
ANN model was chosen for training by exhaustive search 
algorithm (logistic activation function, cross-entropy 
error function and 0.5 accept level). The best network 
was created and trained with a built-in algorithm by the 
batch-back-propagation supervised method whereas the 
initial learning was set at 1.0 and the momentum at 0.8, 
with dynamic adjustment during the iteration procedures. 
The relative importance of input factors in respect to the 
outcome (5-year survival on HD) was calculated using 
the sum of the absolute connection weights from each 
input node to the nodes of the next layer. The stopping 
role of learning during the training procedure was 
assumed as a state of maximum overall correctness of 
prediction (i.e. maximum correct classification rate 
[CCR]) of the validation set (pre-defined at a maximum 
of 95%). The performance of ANN model was assessed 
by receiver operating characteristic (ROC) curve analysis 
Arab Journal of Nephrology and Transplantation
14
Ahmed et al
which test for sensitivity, specificity and accuracy, on 
the whole dataset (overall) as well as on each of the 3 
sub-sets (training, validation and test sets). The larger 
the area under the curve (AUC), the better is the model 
performance (pre-defined as being acceptable if above 
the level of 0.60). Finally, the best predictive model was 
chosen according to the performance criteria e.g., overall 
AUC and model accuracy.
Results
Patients characteristics
The total number of patients included in this analysis was 
93. Median age was 60 years (range: 27-80), 75% were 
males, 23% were diabetics and 80% were hypertensive. 
The 5-year survival was 58%. The baseline and 
1-year follow-up serum biochemistry and hematology 
parameters are shown (Table 1). There was a striking 
burden of comorbidity; 93.5% of patients were found to 
have at least one of the 17 disease conditions, 56% scored 
ICED level two and one quarter of the patients had ICED 
score of three, indicating symptomatic disease, the need 
for medications, or hospitalizations. The most prevalent 
disease was hypertension, present in more than 80% of 
patients, with 50% scored as ICED level two, indicating 
the need for medications. Cardiovascular disease was 
common, with 30% of patients having at least one or more 
of the four cardiac categories. On the second evaluation 
of comorbidity after one year in HD, 53% had no change 
in comorbidity score (ICED level), 31% had one level 
increase and 10% had two level increase. On the other 
hand only 6% had one level decrease, this improvement 
was mainly due to better control of the blood pressure.
Survival
Half of the mortalities were due to cardiovascular 
causes (51%). The second common cause of death 
was sepsis (26%), followed by malignancy (13%). The 
5-year cumulative survival functions, stratified by age 
or comorbidity levels, are presented (Figures 1 and 2). 
Patients who started dialysis at the age of 65 years or 
more had the highest mortality with a 5-year cumulative 
survival of 65%. Also, patients with severe comorbidity 
(ICED level 3) had the highest morality compared to 
other ICED levels with a 5-year cumulative survival of 
around 50%. 
Survival and baseline parameters (group A models)
Among baseline variables, only four variables were 
identified by the Cox model as significant time-to-death 
adjusted independent predictors of 5-year survival in HD 
(Table 2). The independent predictive role of these four 
baseline factors was further studied by logistic regression 
model; this model showed 79.6% sensitivity, 69.2% 
specificity and 75.3% accuracy (Table 3). 
To increase this productivity, these factors were analysed 
further by an ANN model. Many network architectures 
were analyzed and evaluated using the complete dataset 
Table 1: Baseline and 1-year follow up values of serum biochemistry and hematology parameters
Variable Baseline After one year
Urea (mmol/l) 38.4 ± 13.43 24.3 ± 6.6
Creatinine (µmol/l) 929 ± 256 929 ± 287
HCO3 (mmol/l) 21 ± 4.6 23.7 ± 3.4
Ca (mmol/l) 2.27 ± 0.22 2.4 ± 0.2
PO4 (mmol/l) 2.15 ± 0.63 1.9 ± 0.6
Ca X PO4 4.8 ± 1.34 4.5 ± 1.4
Total protein (g/l) 64 ± 8.2 66.4 ± 6.6
Albumin (g/l) 34 (19 - 45) 36.9 ± 5.1
Urate  (µmol/l) 444 (288 - 880) 384 ± 83
Hb (g/l) 9 ± 1.3 10.2 ± 1.8
HCT (%) 27 ± 0.04 31 ± 0.1
ALP (IU/l) 87 (31 - 430) 81 (36 - 520)
Ferritin (µg/l) 370 (46 - 7686) 421 (35 - 2133)
Kt/V _ 1.2 ± 0.1
Data were presented as mean ± SD; median (range) and number (%)
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with these four identified predictors of survival used as 
input variables. The final architecture that reached optimal 
results within a state of higher accuracy and lowest errors 
to predict 5-year mortality consisted of three layers and 11 
nodes, i.e. 4-6-1 design (Figure 3). This network showed 
the highest level of predictive performance as assessed 
by ROC curve analysis; the AUC was 0.90 with overall 
model accuracy of 82.2% (Table 4).
Survival and 1-year follow-up parameters (group B 
models)
The application of both Cox and logistic regression 
approaches neither produced significant models nor 
were they able to order the potential follow-up factors by 
their impact on survival. Therefore, all potential factors 
at 1-year follow-up, including relative percent change 
from baseline, were entered into an ANN model. The 
network was optimized out of 27 most simple possible 
architectures with three layers and produced the order 
of potential predictive importance of the studied factors. 
Only those with a relative importance above 1.5% were 
chosen for further analysis, i.e. serum creatinine change 
(41.7%), hemoglobin change (15.5%), serum phosphorus 
change (13.6%), blood urea change (12%), serum calcium 
change (10.5%), ICED change (2.8%) and serum albumin 
change (1.5%).
Survival and combination (baseline and 1 year follow 
up) predictors (group C models)
We combined the 4 significant baseline predictors 
(group A model) with the follow up predictors (group B 
ANN model) and, together with Kt/V, we constructed a 
multivariate Cox model. The Cox model identified only 
eight independent time-adjusted risk factors for 5-year 
survival (Table 5). These were entered into a logistic 
regression model which confirmed their importance as 
independent predictors of mortality in HD (Table 6), this 
model showed 83% sensitivity, 67.6% specificity and 
76.7% accuracy. These factors were then entered into an 
ANN model and a number of network architectures were 
analyzed and evaluated using the complete dataset with 
the eight independent time-to-death adjusted factors. 
The final architecture that reached optimal results within 
a state of higher accuracy and lowest errors to predict 
5-year mortality consisted of three layers and 15 nodes, 
8-6-1 design, i.e. eight variables in the input layer, six 
nodes in the hidden layer and one node in the output 
layer (Figure 4). The performance of this network was 
assessed by ROC curve analysis which showed high 
level of predictive performance; the AUC was 0.94 and 
the overall accuracy was 93.3% (Table 7).
Discussion
This study investigated the impact of demographic, 
baseline and one year follow up clinical and biochemical 
parameters on five years mortality in HD. It showed that 
at the beginning of HD old age, level of comorbidity 
(ICED score), high diastolic blood pressure (DBP) 
and low systolic blood pressure (SBP) are significant 
predictors of 5-year survival on HD. In addition to these 
four baseline risk factors, this study showed that after 
the first year on HD, low Kt/V, low relative change of 
serum creatinine from baseline, and high relative change 
in blood urea and calcium are important indicators for 
five years mortality. 
Figure 1: Cumulative 5-year survival curves stratified by 
age groups (P= 0.001) 
Figure 2: Cumulative 5-year survival curves stratified by 
ICED comorbidity-score levels (P= 0.000)
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We also found that an integrated approach based on a 
sequential use of Cox regression, logistic regression and 
probabilistic models (ANN) was effective in identifying 
and ordering risk factors for their relative importance in 
predicting mortality in HD. In this sense, a regression 
dilution effect in our multivariate models was unlikely 
to occur due to measurement variability. Moreover, the 
predictive importance of the factors from the multivariate 
regression was confirmed by the ANN modeling in which 
such a dilution effect could not be present.
Several countries have reported an increase in the age of 
patients starting RRT. According to the 2004 UK renal 
registry, the median age of patients started on RRT in UK 
was 64.8 years. In European limb of the DOPPS study 
the mean age was 60.2 years [12]. Old age is the most 
important of the demographic factors associated with 
increased morbidity and mortality in ESRD, and there 
are many reports showing that survival declines with 
increasing age [12-15]. This study is in agreement with 
previous reports that showed that old age is the most 
important independent risk factor for five years mortality 
in HD. 
The presence of comorbid conditions is an increasingly 
common problem, being much more prevalent in new 
patients started on dialysis today than previously [6, 
16-18]. Obviously, the concurrent presence of other life-
threatening conditions, as well as increased severity of 
comorbid conditions will also affect overall survival [8, 
19, 20]. Some studies have shown that the ICED score is a 
strong, independent predictor of death in dialysis patients. 
The risk of death was graded according to the incremental 
levels of the ICED score, and the results were consistent 
and independent of the size or setting of these studies. 
The relationship between the baseline ICED level and 
death remained significant even after adjustment for age, 
serum albumin, and diabetic status [8, 11]. In this study, 
we also found that baseline comorbidity was a strong 
independent predictor of mortality even after adjustment 
for other risk factors. Moreover, we found that graded 
levels of the ICED score were incrementally associated 
with mortality risk.
This analysis also evaluated the change in comorbidity 
over time, utilizing the ICED score. However, changes 
in the ICED level from baseline did not add to the 
baseline level in prediction of subsequent mortality. 
This contradicts the report of  Miskulin and his group 
who found the changes in comorbidity to be a sensitive 
predictor of mortality [8]. However, they measured 
changes of comorbidity over two years, while we had 
a follow up period of only one year. The power of our 
study may have been inadequate to reproduce such an 
association using multivariate analysis, and perhaps 
longer follow-up is needed to demonstrate the effect of 
comorbidity changes on mortality. 
Dialysis adequacy is not easy to quantify, and commonly 
used parameters include control of fluid overload and 
Table 2: Cox survival model with baseline predictors (group A) 
Variable Unit of increase P-value (Exp.B) 95% confidence level for OR
Lower Upper
Old Age 10 years 0.000 1.07 1.037 1.103
High ICED level 1 level 0.000 5.93 2.681 13.129
SBP hypotension 10 mm Hg 0.000 0.95 0.918 0.975
DBP hypertension 10 mm Hg 0.001 1.1 1.041 1.170
Table 3: Logistic regression model with baseline predictors (group A) 
Variable Unit of increase P-value (Exp.B) 95% confidence level for OR
Lower Upper
Age 10 years 0.000 1.09 1.037 1.134
ICED score 1 level 0.001 5.4 2.038 14.332
SBP 10 mm Hg 0.009 0.94 0.895 0.985
DBP 10 mm Hg 0.01 1.12 1.025 1.230
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electrolyte disturbances, correction of metabolic acidosis 
and the dialysis dose. The most frequently used measure 
of the delivered dialysis dose is Kt/V.  To date, there is 
a debate concerning the target dialysis dose that should 
be reached to ensure the best patient outcome [21, 22]. 
The most recent K-DOQI guidelines [23] recommend a 
minimum single-pool Kt/V of 1.2, roughly corresponding 
to a URR of 65%, for thrice weekly HD in patients with 
a residual glomerular filtration rate of less than 2 ml/min 
per 1.73 m2 . The European Best Practice Guidelines of 
2002 recommend higher values: double-pool Kt/V of at 
least 1.2 and single-pool Kt/V of at least 1.4 [24].
A number of observational studies have shown that 
single-pool Kt/V is independently associated with patient 
survival [7, 25]. This report, in agreement with previous 
reports, showed a 9.9% decreased risk of mortality for 
each 0.1 increase in the mean Kt/V during the first year 
of HD. It’s worth mentioning that we did not evaluate the 
effect of higher doses of dialysis on patients’ survival as 
we were limited by the number of patients included in 
this analysis. 
The relationship between BP and the mortality in 
dialysis patients remains controversial. There has been 
considerable discussion regarding whether hypertension 
is a risk factor for mortality or, in reverse, is associated 
with a decreased risk of mortality, as well as to the extent 
to which BP must be lowered to minimize mortality. 
Some authors argue that low normal BP values are 
associated with increased mortality and that moderate 
hypertension provides optimal survival [26-28]. Whether 
low BP values simply indicate high comorbidity scores 
or directly reduce life expectancy remains unclear. In the 
dialysis population, a significant correlation between low 
predialysis SBP and mortality has been reported by several 
studies based on large cohorts of patients [12, 28, 29], 
and our finding agree with these reports. This probably 
reflects advanced cardiovascular disease (CVD), since 
low BP values often characterize patients with poor cardiac 
function and high risk of cardiovascular death. Another 
potential confounding factor could be that patients with 
low pre-dialysis systolic BP may receive shorter dialysis 
sessions, or that they are at increased risk of intradialytic 
hypotension. Indeed, the risk of death among high risk 
diabetic hemodialysis patients was increased by a factor 
of 3 when two or three hypotensive episodes occurred 
per week [29]. Even if frank hypotensive episodes do not 
occur, it is plausible that massive sympathetic activation 
is provoked by ultrafiltration in patients with pre-existing 
cardiac disease, and this is a deleterious factor contributing 
to cardiac arrhythmia and cardiac ischemia. However, we 
did not observe the U-shaped curve relationship between 
SBP and mortality that has been mentioned in previous 
studies [27, 28]. 
In the present investigation high DBP was found to be 
an independent risk factor for mortality. The risk of 
death was increased by 9% per one mmHg increase in 
the DBP. However, some authors found that low rather 
than high DBP predicts mortality [30]. A third group of 
authors described a U- shape relationship between DBP 
Figure 3: ANN model with baseline predictors (group A 
model)
The final architecture that reached optimal results consisted of 3 layers 
and 11 nodes (4-6-1 design), i.e, 4 variables (grey triangles on the left) 
in the input layer, 6 nodes (grey circles) in the hidden layer and one 
node (grey triangle on the right) in the output layer
Table 2: Cox survival model with baseline predictors (group A) 
Sets Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)
Training 80 81.1 80.6 74 87
Validation 100 90 92.9 80 100
Test 67 86 78.6 80 78
Overall 80 84 82.2 76 87
PPV: positive predictive value, NPV: negative predictive value
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and survival in HD [28]. Indeed, high DBP is a risk factor 
for CVD and late mortality, while low DBP identifies 
patients with advanced CVD and hence implicates a 
higher risk of early mortality. 
Although this study failed to demonstrate some of the 
previously reported associations between baseline 
biochemical parameters and survival, it has clearly 
shown that changes of some of these parameters (serum 
creatinine, blood urea and serum calcium) during the 
follow-up period had a negative impact on survival. In 
dialysis patients, the serum creatinine concentration relates 
to nutritional status and reflects somatic protein stores, 
muscle mass and dietary protein intake. Hence, low serum 
creatinine levels have been shown to be highly predictive 
of mortality in HD patients [31-33]. As confirmed before, 
mortality risk in this study was associated with lower 
relative change in serum creatinine levels after one year, 
that is, less increase in serum creatinine level over one year 
of follow-up. Each 1% increase in the relative change of 
serum creatinine level was associated with 3% increase 
in survival. Low serum creatinine levels reflect small 
muscle mass or malnutrition; factors which have been 
shown to be associated with comorbidity [7, 11, 31-35]. 
It is worth noting that the change in serum creatinine 
level over time may be more important than absolute 
values, since well-nourished well-dialyzed patients may 
have relatively lower serum creatinine levels than similar 
patients undergoing inadequate dialysis.
Urea is the most frequently used marker in measures 
of dialysis adequacy. The national co-operative dialysis 
study (NCDS) reported that blood urea nitrogen (BUN) 
was an important determinant of morbidity in patients 
undergoing HD [21]. Later, the same group found a U- 
shaped association between BUN and survival in HD 
[31]. They speculate that the higher mortality in the high 
BUN group is due to relative under-dialysis, while the 
higher mortality in the low BUN group may be due to 
under-nutrition. In this cohort, higher relative change of 
blood urea level after one year, that is a greater increase 
in blood urea levels after the first year, is a significant 
risk of mortality, with a 4% increase in the risk of death 
for each 1% increase in the relative change of the blood 
Table 5: Cox survival model with baseline and 1-year follow-up predictors (group C)
Variable Unit of increase P-value (Exp.B) 95% confidence level for OR
Lower Upper
Age 10 years 0.000 1.07 1.034 1.102
ICED score 1 level 0.000 5.69 2.515 12.856
Kt/V in the first year 0.1 0.000 0.007 0.001 0.097
DBP 10 mmHg 0.006 1.094 1.026 1.165
SBP 10 mmHg 0.02 0.96 0.932 0.993
Blood urea change 1% 0.01 1.02 1.002 1.030
Serum creatinine change 1% 0.002 0.98 0.962 0.994
Serum calcium change 1% 0.059 1.46 0.985 2.175
Table 6: Logistic regression model with baseline and 1-year follow-up predictors (group C)
Variable Unit of increase P-value (Exp.B) 95% confidence level for OR
Lower Upper
Age 10 years 0.000 1.12 1.053 1.185
ICED score 1 level 0.000 8.74 2.717 28.115
Kt/V in the first year 0.1 0.001 0.001 000 0.041
Serum creatinine change 1% 0.008 0.97 0.949 1.000
DBP 10 mmHg 0.04 1.13 1.007 1.258
SBP 10 mmHg 0.04 0.94 0.888 0.998
Blood urea change 1% 0.05 1.04 1.010 1.068
Serum calcium change 1% 0.054 1.83 0.990 3.399
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urea.  It is possible that high blood urea level acted as an 
indicator of inadequate dialysis.  
Previous reports have identified associations between 
certain disorders of mineral metabolism and all-cause 
and CVD mortality in HD. In the present study, high 
relative change in serum calcium level from baseline, i.e. 
a greater increase in serum calcium level after one year 
on dialysis, was a significant independent predictor of 
mortality (RR of 1.46). These results contrast with results 
reported earlier by Foley and colleagues, who found that 
low serum calcium (< 8.8 mg/dl) was associated with 
increased mortality [35]. 
We found no association between mortality and some 
of the well established risk factors, i.e. serum albumin 
and phosphate levels, calcium phosphate product, 
hemoglobin, hematocrit, body mass index and smoking. 
It is possible that these factors simply identify less healthy 
patients and serve as a convenient clinical surrogate for 
comorbidity assessment, rather than having a direct 
causal relationship to survival.
A major strength of the present study is the integrated 
approach, with sequential use of univariate and multi-
variate Cox regression analysis and the ANN models. 
This might lead to the development of optimum prediction 
models. A regression dilution effect in this multivariate 
model was unlikely to occur due to measurement 
variability. Moreover, the predictive importance of the 
explanatory factors from the multivariate regression was 
confirmed by the ANN modeling in which such a dilution 
effect could not be present. This approach is flexible and 
it can be adopted by physicians and policy makers in 
order to optimize the performance of the model. 
This study also compared the performance of ANN models 
against logistic regression models in predicting mortality 
in HD. Both logistic regression and the ANN models 
did well in predicting mortality in HD. However, ROC 
curve analysis proved that ANN models significantly 
outperformed logistic models in all aspects; sensitivity, 
specificity and accuracy. Currently, the logistic regression 
and the ANN are the most widely used models in outcome 
studies. One of the advantages of ANN analysis is that 
it allows the inclusion of a large number of variables 
and can deal with non-normally distributed data [36]. 
Another advantage of the ANN approach is that the ANN 
is not constrained by predefined assumptions between the 
dependent and independent variables and can powerfully 
model complex non-linear relationships [36]. One of the 
strengths of the ANN is its ability to find patterns despite 
missing data [36]. Neural networks have perhaps a 
Figure 4. ANN model with combined baseline and 1-year follow-up predictors (group C models)
The final architecture that reached optimal results consisted of 3 layers and 15 nodes (8-6-1 design), i.e. 8 variables (grey triangles on the left) in the 
input layer, 6 nodes (grey circles) in the hidden layer and one node (grey triangle on the right) in the output layer
Arab Journal of Nephrology and Transplantation
20
Ahmed et al
special appeal to the medical community because of their 
superficial resemblance to the human brain, a structure 
with which most physicians are comfortable, and seem 
to promise prediction without the difficulties associated 
with use of mathematics [36]. 
Conclusion 
A high ICED score, old age, low SBP and high DBP 
at commencing HD predicted low 5-year survival 
rates. In addition, the percent changes from baseline in 
serum calcium, blood urea, serum creatinine as well as 
inadequate dialysis during the first year on HD were 
independent predictors of 5-year mortality. The individual 
mortality risk index, computed by the integrated use of 
regression analysis and probabilistic (ANN) models, 
allowed prediction of outcome using a combination of 
factors and could provide useful information on health-
associated issues such as mortality, quality of life or cost 
of treatment. Such models also help to identify high risk 
subjects in order to intensify monitoring, prevention and 
treatment protocols, with the final goal of optimizing 
care and minimizing costs. 
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